PROVETOP

Biotinylated Cynomolgus IL-6 Protein

Catalog No: IL6-CB002

Species
Cynomolgus
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Cynomolgus IL-6 Protein is expressed in HEK293 cells with a His tag and Avi tag at the N-terminus. It contains amino acid residues Ala28-Met212 (UniProt accession: P79341).

Product Details

Molecular Aliases
IFN-beta-2; IL6; IL-6; BSF-2; CDF; MGI-2A; Interleukin-6; HSF; IFNB2; HGF;IFN-β-2;BSF2; MGI2A;IFN-b-2; IFN-b2;Interleukin 6; IL 6
Protein Length
Ala28-Met212
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 23.87 kDa. Due to glycosylation, the protein migrates to 27-35 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
IL6-CB002 Bis-Tris-PAGE-white result

Biotinylated Cynomolgus IL-6 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
IL6-CB002 SEC-HPLC result

The purity of Biotinylated Cynomolgus IL-6 is greater than 95% as determined by SEC-HPLC.

ELISA
IL6-CB002 ELISA result

Immobilized Human IL-6 R alpha, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Cynomolgus IL-6, His-Avi tag with the EC50 of 0.16μg/ml determined by ELISA (QC Test).

Background

IL-6 (Interleukin-6) is a pleiotropic cytokine that acts in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression.Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein.

References

  1. Gabay C. Interleukin-6 and chronic inflammation[J]. Arthritis Research & Therapy, 2006, 8.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support